AVM0703 Could Be the First Choice for Patients Without Options
Clinical Trial Enrollment
AVM is enrolling patients in the AVM0703-001 or “WWRD” study, an open-label adaptive design expansion cohort pivotal Phase 1/2 study in Relapsed/Refractory Non-Hodgkin’s Lymphoma at major cancer treatment centers in the US. Phase 1 is dose-finding and Phase 2 is intended to determine efficacy. Patients in Phase 1 can retreat in this trial at the highest, most effective, and safest dose identified from dose-finding. It is believed that AVM0703 can induce remission or sufficiently improve patient’s health so they may tolerate other treatments, such as hematopoietic cell transplantation (HSCT) or cell therapy protocols. The U.S. Food & Drug Administration has given AVM permission to begin clinical trials with AVM0703 in patients with a variety of lymphomas, i.e., mantel cell lymphoma (MCL), primary mediastinal large B-cell lymphoma (PMBL), Burkitt or Burkitt-like lymphoma/leukemia, chronic and small lymphocytic leukemias (CLL/SLL), B-lymphoblastic leukemia/lymphoma, T-lymphoblastic leukemia/lymphoma, acute leukemia/lymphoma, acute leukemias of ambiguous lineage or natural killer (NK) cell lymphoblastic leukemia/lymphoma. More information can be found here on ClinicalTrials.gov, NCT04329728.
Patients who do not meet requirements for this clinical trial may be eligible for AVM0703 via AVM’s Compassionate Use or Expanded Access Program.